In this issue:
Real-world immunotherapy use in NMOSD & MOGAD
Rituximab as first-line vs. escalation treatment in AQP4-IgG+ NMOSD
AIGA-associated AOID
WAYPOINT: tezepelumab in severe chronic rhinosinusitis with nasal polyps
INCEPTION: tezepelumab in chronic spontaneous urticaria
Features of NK cell deficiency
Prevalence/features of CKD in in common variable immunodeficiency
Knocking out SMAD4 in human NK cells to prevent TGFβ & activin A suppression
Overall survival with early vs. late SCID diagnosis
Long-term efficacy of leniolisib in APDS
Please login below to download this issue (PDF)